In the U.S., the Regeneron COVID-19 antibody ran $2,100 per dose to the government; patients typically paid $0 while it was available.
Editor’s note: People often use “Regeneron treatment” to mean REGEN-COV (casirivimab and imdevimab) for COVID-19. That product is no longer offered in the United States. This guide explains what it cost while in use, what providers were paid to give it, and how to read old bills or news posts about the price.
Cost Of The Regeneron Antibody Infusion — Real-World Numbers
During the emergency-use period, the federal government bought doses directly and shipped them to infusion sites. The purchase price was about $2,100 for a 1,200 mg course. Patients did not purchase the drug; sites received supply from the federal stock, and the medication line on a bill showed $0 to the patient. The usual charges you’d see were for the act of giving the infusion or injections, plus any facility fee at a hospital-based clinic.
| Cost Item | Typical Amount | Who Paid |
|---|---|---|
| Drug acquisition (per dose) | ~$2,100 | Purchased by U.S. government |
| Administration in facility | ~$450 (national average) | Insurer/Medicare; $0 to Medicare patients |
| Administration at home | ~$750 (national average) | Insurer/Medicare; $0 to Medicare patients |
Those administration figures reflect Medicare’s national rates during the public health emergency. Many commercial plans paid in a similar ballpark for the service. People covered by Medicare owed $0 for both the drug and administration under that policy.
Availability Today And What That Means For Price
As of December 13, 2024, the U.S. Food and Drug Administration revoked the emergency authorization for casirivimab and imdevimab. Regeneron indicated that lots had expired and that it did not plan to offer the product in the United States. In practice, there isn’t a current U.S. retail price because providers no longer stock or administer this antibody.
When you see dollar amounts online, they almost always describe the 2021–2022 period. Back then, the government bought supply and sites billed payers for giving the infusion. That is why older articles mention a per-dose figure and a separate service payment.
How The Price Was Structured During The EUA Era
Two moving parts determined what showed up on a claim or Explanation of Benefits (EOB):
1) The Drug Cost
The government purchase price hovered around $2,100 per dose. That number mattered for budgets and forecasting, not as a point-of-sale price to a patient. Infusion centers received doses from federal supply and did not charge patients for the medication itself.
2) The Cost To Administer
Medicare published national averages for the service of giving the therapy. Sites received about $450 in a standard facility and about $750 when a clinical team administered it in a patient’s residence. Those payments were meant to cover nursing time, equipment, and the one-to-one nature of home visits. During the public health emergency, people with Medicare had no cost sharing for these services.
Who Might Still See A Charge Today?
Old claims can surface due to audits or coordination of benefits. If you receive a statement with dates from the emergency-use period, expect to see:
- A $0 drug line or language stating the antibody was supplied from federal stock.
- An administration fee reflecting the infusion or injections.
- A facility fee if the site was a hospital-based infusion center.
If a statement shows a non-zero medication charge for casirivimab/imdevimab, contact the billing office and ask whether the line should have been adjusted to $0 because the supply came from the federal program.
What If You Meant A Different Regeneron Medicine?
Regeneron develops several products unrelated to COVID-19, such as aflibercept for certain eye conditions and dupilumab for allergic or inflammatory diseases. Those medicines have separate pricing, dosing, and insurance rules. If your goal is to learn the cost of a different product from the same company, gather the exact brand name, strength, and dosing schedule. Prices vary widely by indication and benefit design.
Why The Antibody Stopped Being Used In The U.S.
Over time, circulating variants limited the lab activity of several COVID-19 antibodies. In early 2022, use was paused regionally as variant patterns shifted. The authorization was later revoked after supplies expired and the sponsor requested the change. Care pathways moved toward oral antivirals and other options recommended in national guidelines.
How To Decode Bills And EOBs Related To The Antibody
Use this quick reference to make sense of older claims and line items:
Common Line Items You’ll See
- Drug charge: Often $0 or marked as supplied by government stock.
- Administration fee: A CPT/HCPCS code for IV infusion or subcutaneous injections with an allowed amount in the few-hundred-dollar range under Medicare policy.
- Facility fee: A site-of-care charge that hospital-based clinics bill in addition to professional services; amounts vary by center and payer contracts.
Two Scenarios That Explain Past Pricing
Scenario A: Hospital Infusion Suite
You qualify and visit a hospital-based clinic. The clinic uses federal inventory for the medication, bills your plan for administration, and may include a facility fee. Under Medicare rules at the time, the drug line shows $0, the administration line reflects the national average, and the facility fee depends on the hospital’s schedule and the payer contract.
Scenario B: Home Administration
A clinical team brings the medication from federal supply to your residence. The claim lists the at-home administration service. Medicare allowed a higher payment for this model to cover travel and the one-to-one visit.
What Drove The Dollar Amount
Several practical factors shaped the payment range for administration:
- Staffing and time: Infusions require nursing time for screening, setup, and observation.
- Supplies: IV lines, PPE, and emergency-response equipment add fixed costs.
- Setting: Hospital-based clinics can bill a facility component; independent offices usually cannot.
- At-home logistics: Travel time, transport coolers, and one-patient visits drove a higher allowed amount.
If You See Different Numbers Online
Price labels vary. Here’s how to read them:
- Contract price: The government’s per-dose purchase cost (~$2,100). This was not a patient charge.
- Allowed amount: The payer-negotiated payment for a service like an infusion. Medicare published national averages (about $450 in facilities and about $750 at home).
- Chargemaster rate: A provider’s list price before payer discounts. This can be much higher than the allowed amount and often doesn’t reflect what a plan actually pays.
Outside The United States
Regulatory status and supply arrangements differed by country. Where public systems negotiated purchase contracts, patients typically didn’t pay a retail price for the medication itself. If you’re researching historic costs outside the U.S., look for health-ministry announcements or contract summaries rather than clinic list prices.
Authoritative Sources Behind The Numbers
The federal contract price and “no cost to patients” language came from the company’s September 14, 2021 announcement. Medicare’s national payment figures and $0 patient cost sharing were set in a May 6, 2021 notice for monoclonal antibody infusions. The current U.S. status stems from the FDA’s Federal Register notice stating the authorization was revoked effective December 13, 2024. You can read the FDA revocation notice and the Medicare payment policy for confirmation; both pages open in a new tab:
Quick Answers To Common Cost Questions
Is There A Current U.S. Price?
No. The product is not offered in the United States. Any dollar figure you see reflects the period when government purchases were active.
Did Patients Pay For The Antibody?
People with Medicare owed $0 for both the drug and administration under the public health emergency policy. Many other payers treated the drug line as $0 because supply came from federal stock.
How Much Did Providers Get Paid To Give It?
Medicare’s national averages were about $450 in facilities and about $750 for at-home administration. Commercial plans varied but often paid in a similar range for the service component.
What To Do If You Still Need COVID-19 Care
Members of this antibody family are not in U.S. use. If you test positive and are at risk, ask a clinician about time-sensitive oral antivirals and the current recommendations in national guidelines. For those with weak immune responses who seek preventive options, ask your clinician about the latest prophylaxis choices that regulators have cleared in your region.
Provider Checklist: Questions To Ask About Costs
Use these prompts to get precise answers from a billing office or infusion site when your claim dates fall within the emergency-use window:
| Topic | What It Means | What To Ask |
|---|---|---|
| Drug source | Whether the antibody came from federal stock | “Was the medication from the federal program, so the drug line should be $0?” |
| Administration code | The CPT/HCPCS billed for infusion or injections | “Which code did you bill and what was the allowed amount?” |
| Site-of-care fees | Clinic or hospital charges separate from the infusion | “Is there a facility fee and how did you calculate it?” |
Method Notes
This guide sources dollar figures and policy language from primary materials published during the public health emergency. The $2,100 per-dose contract and “no cost to patients” statement came from the September 14, 2021 company announcement. The administration payment levels and $0 Medicare cost sharing came from a May 6, 2021 Medicare press release. The present U.S. status comes from the FDA’s Federal Register notice published July 29, 2025, which states the authorization was revoked effective December 13, 2024.